Bayer Moves Anti-Thrombotic Into Phase III For Two Indications

Bayer is set to begin Phase III trials for its antithrombotic agent BAY 59-7939 for a general venous thromboembolism indication following promising Phase II results, the company announced June 12

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet